Characterizing Sensitivity to Vincristine, Irinotecan, and Telomerase-targeted Therapy in Diffuse Anaplastic Wilms Tumor Patient-derived Xenografts☆

In brief

This study evaluates chemotherapy sensitivity and novel telomerase-targeted treatments in patient-derived xenograft models of diffuse anaplastic Wilms tumor, a high-risk pediatric kidney cancer with poor outcomes. The research explores vincristine and irinotecan responses alongside telomerase inhibition as potential therapeutic strategies for this challenging malignancy.

• Diffuse anaplastic Wilms tumor (DAWT) has poorer prognosis compared to other Wilms tumor subtypes.
• Telomerase upregulation is a key mechanism in DAWT pathogenesis and represents a targetable vulnerability.
• Patient-derived xenografts enable preclinical testing of vincristine, irinotecan, and telomerase-targeted therapies for DAWT.
• Characterizing drug sensitivity in DAWT models may guide personalized treatment strategies for high-risk patients.

Written by the GCMD Library team from the article.